rosiglitazone has been researched along with Esophageal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Isozaki, Y; Maruyama, T; Matsubara, H; Mori, M; Murakami, K; Nakayama, T; Nishimori, T; Suito, H; Suzuki, A; Takahashi, M; Takeshita, N; Toyozumi, T | 1 |
| Liu, D; Qi, Y; Wu, K; Yang, Y; Zhang, C; Zhao, J; Zhao, S | 1 |
2 other study(ies) available for rosiglitazone and Esophageal Neoplasms
| Article | Year |
|---|---|
Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map.
Topics: Antineoplastic Agents; Apoptosis; Benzocaine; Betazole; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Chenodeoxycholic Acid; Cytotoxins; DNA Primers; Esophageal Neoplasms; Humans; In Situ Nick-End Labeling; Metformin; MicroRNAs; Nizatidine; Organophosphates; Proline; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcriptome; Transfection; Tumor Suppressor Proteins | 2014 |
Activation of PPARĪ³ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; PPAR gamma; RNA Interference; Rosiglitazone; Thiazolidinediones; Time Factors; Toll-Like Receptor 4 | 2016 |